silver lining about performance, prices get cheaper, the bigot ovation is obesity drugs in like eli lillynordisk. we have only eli lilly and novo nordisk for the last ten years and initially were excited about the diabetes franchise, they've taken the same medicines which are called glp-1's or incurred of invasive therapies and develop them for obesity and obesity is potentially the biggest market that i've ever seen in my career. to give you a sense, these products are already in utilizing out over $40 billion and growing over 35% as a first quarter, is widely expected this will be 100 billion-dollar market in the penetration if you look at the 800 million people that have obesity that are in the low single digit, huge growth opportunity ahead for these companies for the market leaders. jack: that's a very large tam total adjustable market, another company in the hunt not year that amgen that drug might be better than the competitors. >> first of all lily and novo are not standing still the goal is obsolete their own products with better products and as good as the products are today, hi

the boss of us pharma giant eli lilly addresses concerns, as generic weight—loss drugs become more accessiblello and welcome to business today. i'm steve lai. as we kick off a new month and the official start of the second half of 2024, let's recap some of the key challenges the global economy faced over the past 6 months. in the us, the federal reserve has not provided much clarity on lowering the cost of borrowing, as the economy grapples with a major cost of living crisis. china's growth recovery is also concerning amid a persistent property crisis and soft domestic consumption. for clues on what the second half of the year could bring, i'm joined byjameel ahmad, if you look at this of the 500, and record highs of 35 and those of the types of records that be taking place that cristiano ronaldo would be jealous of mr v catnip it wasn't as us stock markets but those all—time highs and bit coin, gold and we should talk about the supercharge as well becoming the largest company in the world market capitalisation were generally speaking, some solid fundamentals despite the policy pretty much ge

in an open letter, eli lilly, the maker of mounjaro, said it was deeply concerned about growing onlineed phony or compounded versions of zepatide, the active ingredient in its drugs. eli lilly says people should never buy the drugs through social media or med spas. >>> vitamix is recalling more than half a million blending containers and blade bases sold across the country. this after reports of more than two dozen lacerations. the manufacturer says the containers can separate from the blender's blade base which can then expose the blades and pose danger. anyone with the recalled products should contact vitamix for a protective plastic piece to attach over the blade base. >>> and another fast food deal this summer. mcdonald's is introducing a $5 meal deal which includes four items -- you can pick a mcdouble or mcchicken, four-piece chicken mcnuggets, small fries, and a small soft drink. the deal is only available at participating restaurants and for a limited time. >>> that's your cbs "moneywatch" report for this friday morning. i'm shanelle kaul, cbs news, new york. >>> well, ahead, t

i have more blackie ing breakin regarding the fda and eli lilly. update. >> yeah, scott, the fda advisers are voting unanimously that eli lilly's alzheimer's drugs, the benefits outweigh the risk. that drug slowed the progression by 29% in a phase 3 trial but did come with the risk of side effects that include brain swelling and bleeding. those side effects can be deadly. the advisers today saying they feel like the benefits outweigh those risks and that these risks can be managed with close monitoring. they're talking now about those decisions. we'll tune in and we'll be back with anything else we hear out of that. scott? >> i appreciate that very much. thank you for the update. angelica. back to the conversation we were having, where mike left off, the idea of the market, its patience or lack thereof, when it might become lack thereafoff before t first rate cut? >> i think mike is exactly right. the type rote they had been on is they're relatively resilient. we are seeing some signs that the last two years of the economic environment, including t

kenvue, even though it is generic it does conflict too much with eli lilly. we will go put in right here procter & gamble and then and only then would i be satisfied with diversification. next, how about we go to tom and florida. >> i am an investment club member and second time caller. thank you for your help with everything. my stocks are apple, coterra, dell. we have apple and dell which are conflict. we have coterra. ge healthcare. i like this. they have to make this quarter or i will be very upset. then there is stanley black & decker. these are both excellent. tom is an investor of the investing club which i which -- wish everybody elsewhere. i'm thinking why not add abbott labs. we have a lawsuit that is going to start in missouri. it will mean that much to the company but it will freak out investors. that's where i pulled the trigger. now we will go to bonnie in michigan. >> first of all, thank you so much. i just joined the club in january. a lot of blessings to you and your family. >> thank you. >> you are such a good guy. >> he's a good man. >> so

also in pharma, eli lilly saying it will work with open ai to develop novel treatments for drug resistantlilly and novo touching headlines and alnylam, a 6% gain after yesterday's 35% move higher at the biotech etf today. what do we want to trade now? guy? >> tim alluded to it yesterday. just in the math of eli lilly and this has been true in for a while. it's done $52 million in revenue, by comparison merck will do $68 billion and one-third the size. there's something a skew here. i'm not saying sell eli lilly, and there will never be equals in this environment and merck given that math is still the stock you want to own. it's at an all-time high. >> the two have united into one story today. ai and weight loss. >> here's a question for you because i saw this great doc a few months ago on cnbc called big shy. >> you can watch it. >> when you see it, wegovy, it doesn't matter because it won't be there for years and they don't have the supplies. i'm curious, how do you think about that? if that's the thing driving price performance today, and it gives you greater confidence in the future an

table from eli lilly.investment ideal here as well. davey: alphabet has really shifted its focus and turned to generative ai as its mission and the thing it is pouring its investment into. as it's done that it has also let some of its moonshot health care efforts languish and i think that she can bring some revitalization to those efforts. so we will see how it goes. ed: as you know, every quarter for the last year i got to ask ruth when they would have a new cfo and each quarter she would also point out she is doing other stuff while they are looking for a new cfo she's technically been president and chief investment officer and in that time, alphabet has done well, what we know about the big picture plan for her and what she will be focused on or where she is going? davey: ruth is a pretty legendary figure in the tech industry. she oversaw alphabets restructuring when google blew up its corporate structure and created these tiny companies under alphabet. she has also grown the company in its cloud and u2

eli lilly announcing new lawsuits against wellness centers and medical spas that advertise their drugsay they never sells medications on social media. you can follow the latest company buzz on the terminal. the s&p 500 is still green but just so, up .1%. we were at higher by about .3% earlier but giving up some of the gains. looking at big tech, flipped into negative territory. the nasdaq 100 currently off by .1%. all as a yields continue to climb higher. the two year treasury yield higher by three basis points. coming up, ev charging wherever you go. chargepoint and lg are forming a partnership. the ceo joins me next. this is bloomberg. ♪ sweat isn't sweet. it's salty. lmnt. more electrolytes. zero sugar. you feel the difference when you get it right. stay salty. katie: chargepoint and lg announcing a new partnership this week. the companies are making -- aiming to make ev chargers more accessible to consumers. here with more is abigail doolittle. >> the stock is responding positively. there is this announcement that lg electronics is partnered with chargepoint to expand is ev chargin

and eli lilly higher again today.nd its weight loss drug zepbound to treat sleep apnea after positive trial results. cpap makers all dropping on this news what do you want to trade? >> well, i think with lilly, as much as we want to throw them in the same boat as nvidia, because of what they're doing in the health care sector relative to the innovation to nvidia, the fact of the matter is, this is one where they are so far ahead. we talked about the exciting alzheimer's news last week, and the blocking and tackling in sleep apnea that continues to show they're beating up the competition. there's a lot of people waiting for a pull-back to own this one. >> it's amazing that these names continue to trade lower on the same news. it's not like the first time we've heard that zepbound can help sleep apnea >> we've seen it across a swath of industries. the same news moves the stocks at different times other names are starting to -- not nearly to the extent, but merck made an all-time high. gilead not a great day today, becau

the eli lilly could be a competitor.s is a crucial time we have to make investment decisions where you have more cash coming in. is that how you view it? >> yes, it's a bit occult -- to put a bit of color around it, the same forecast predicts there will be a billion people living with obesity in 30, 35. we are serving one to 2 million of those today. so there is a place for more. then you are right, in most markets where you get more competition, and also at a time pricing moves down and you start treating those who accept the higher price point in the u.s. debt commercial insurance and over time you get broader access and patience payer -- paying a load price. if you just take our leading diabetes product in the u.s. since the launch in 2018, the price we get after the rebound, etc. is 40% lower than when we launched. that's often not mentioned in the political debate. instead, the list price is mentioned, which is not what we put in our account. francine: the u.s. is a large market would you ever delist or change headq

we know of eli lilly, and amgen could be a competitor.nd so this is i guess a crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one or two million of those today. so there is a huge market opportunity here, and there is a place for more. and you are right. in most markets, when you get more competition and also, over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and, over time, you get broader access and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead, the list price

you're looking at eli lilly. what's new there? lauren: up about 1%. it hit a new high moments ago.e group of advisers to the fda that today is reviewing eli lilly's alzheimer drug. do the benefits of slowing outright crime benefit the risk to the brain. eli lilly shares are higher because it's expected that it gets the green light and typically the fda will rule against the crowd strike. it's up for the record high and added to s&p 50 along with go daddy up and 10.5% and gamestop, ash. i know it's a game and investors and retail was disillusioned on friday and earlier in the show, microsoft is selling an x box console this holiday season without a disk drive. ashley: kathy hochul going for the pricing plan. lauren: they're only going to focus on basic operations and keeping everything running and a lot of projects will be put here and making stations more accessible and mta right now is in limbo and has a billion hole in their budget and the governor's alternative plan taxing small businesses in the state was shot down immediately. she hasn't come forward since then and calling her

eli lilly has some positive news of outcomes. i'll give you the latest on the healthcare stand up and it's progress. one of the key players making strides, we discussed the name. we will see where the energy company stands with record- breaking efficiency so stay with cramer . >> don't miss a second of mad money follow at jim cramer on ask. give us a call one 807 43 cnbc. power e*trade's award-winning trading app makes trading easier. with its customizable options chain, easy-to-use tools, and paper trading to help sharpen your skills, you can stay on top of the market from wherever you are. e*trade from morgan stanley (office chatter) is it me...or is work not working? at least, not the way it could work. your people are buried in busy work. and you might be thinking... can ai make it all work? can ai help your people work... without all the workarounds? feel better. make customer service work the way customers expect? that one. make your old tech work with your new tech? thank you. and todd here is wondering, can ai do all that

teresa: yes out a panel of the fda advisors, unanimously agreed that eli lilly's new out as good whenlly of timeline and when the fda might actually take action on that but is still really good news. anti- —-dash antibodies are very tricky drug to administer and so this is only good for eli lilly before drugmakers across the spectrum at that might want to make these kinds of drugs you need a lot of infrastructure because the patients need to be constantly monitored and go to centers and fusions when they have this so what is good for one drug is good for the whole class. jack: okay switching to a health concern didn't want no reason to panic at the disturbing developing of the bird flu front. teresa: that is right is so unfortunately, what was discovered in the muscle tissue injury help now is no reason to panic but it is concerning to seated do parts of the cal because it means more widespread disease and also there's new routes a possible transmission again this was an account that was going to be consumed so a lot of safeguards in place but at the same time, we want to continue to

eli lilly is paving the way for alzheimer's drug.t would become the second alzheimer's drug of its kinds behind the treat from biogen. shares of eli lilly up 3%. huntington bank largest decline since 2023. lowering guidance saying a smaller amount of net interest income this year. they are rebounding and up fractionally. huntington is the 25th largest u.s. bank by total assets holding 153 billion of deposits. >>> now to energy. natural gas crossing back above the $3 mark for the first time since january but not the summer heat feeling the need for more energy. we have the role that artificial intelligence is playing in the demand for power. >> this is all about data centers and energy is the backbone here with mackenzie forecasting that power consumption from data centers in the u.s. alone will more than double by 2030. wells fargo put it, quote, gas to the rescue. location is important since companies closest to demand growth centers could have the most upside. drillers like the ones on your screen all have operations in the northea

so i have some breaking down your orders, the new eli lilly obese, the medication, i want more and i know i shouldn't zip about actually was or the ball. i'm going to check if a new drug is not superior to its predecessor with a new product. we'll drop in price and you don't earn anything. did you know each? there's huge competition to have the best new product you new assume difficult. the development of artificial g, l p one is still in its infancy. while the market is booming, obesity experts say the new drugs are not a solution to the problem for you. i'm the owner of this house. oh yeah, and girl triumeq the food industry still has a lot of work to do. we have a quality seo, the same goes for politicians whose duty it is to help us improve the ingredients of products on sooner. does that anymore, wants to, to the we know that certain foods contain a lot of sugar, which you could see and because that makes them taste better, it makes them sell better to buy proof be so wash the substitute for this we as a society could decide to limit the amount of sugar and so to drink, the inte

that will make eli lilly a trillion dollar company before you know it. the weight loss drugs. give me your macro picture. what will serve as the catalyst for the second half? >> right now it is coming down to earnings. the first-quarter earnings were, we saw positive earning growth from the s&p 500. you will want to stick with the large caps, large over small if you will. that is going to continue to work for the back half of this year. we anticipate we'll get some help from the fed, maybe september, maybe the day after the election in november and that will also help accelerate. but the at end of the day, earnings, last 12 quarters of earnings we saw profitability, profit margins of the s&p 500 up 12%. liz: great to have you. thank you so much for joining us. folks, tomorrow subway north american president douglas frye. ♪. larry: hello, folks, welcome to "k

80 novo and eli lilly are at the tom sent me to come, but they are over 50 obesity drugs currently in development. the more specific on after completely underestimating the market, the competition has now working up weakness. so just give me some, i'll shoot you all told to some of the home bound, which is gaining attention for its potential to provide powerful results in treating obesity. so i have some breaking down draw news. the new eli lilly obese, the medication, i want more and i know i shouldn't zip about actually because of the ball. i'm going to tell you if a new drug is not superior to its predecessor, the new product will drop in price and you don't earn anything there's, you know, each, there's huge competition to have the best new product. you know, of us from the development of artificial g, l p one is still in its infancy while the market is booming. obesity experts say the new drugs are not a solution to the problem for you. i'm the owner of this house. oh yeah. and girl triumeq the food industry still has a lot of work to do. we have a policy see on the same goes for

the new eli lilly obese . the medication i want more and i know it shouldn't zap about and actually it was a repo. let me tell you if a new drug is not superior to its predecessor with a new product, we'll drop in price and you don't earn anything. virginia beach, there's huge competition to have the best new product, but you know, as soon as you felt the development of artificial g, l, p one is still in its infancy, while the market is booming, obesity experts say the new drugs are not a solution to the problem, where are you? i'm the owner of this house. oh yeah. and girl triumeq is the food industry still has a lot of work to have a quality seo. the same goes for politicians whose duty it is to help us improve the ingredients of product one sooner does adding more on say to the we know that certain foods contain a lot of sugar, which you could see. and because that makes them taste better, it makes them sell better by proof be. so we'll actually substitute for this. we use this as soon as he could decide to

eli lilly has already asked the fda for approval to treat the condition. >>> taylor swift mania takingondon and the british royal family. prince william celebrating his 42nd birthday with a trip to the "eras" tour concert. william spotted dancing in the stands to "shake it off." he later posed for selfies backstage with prince george and princess charlotte. >>> when we come back, the young man determined to continue his passion despite a devastating injury. e his e his i was born to live in the limelight. but psoriasis kept me in the shadows. until i got clearer skin with bimzelx. most people got 100% clear skin. some after the first dose. serious side effects, including suicidal thoughts and behavior, infections and lowered ability to fight them, liver problems, and inflammatory bowel disease, have occurred. tell your doctor if these happen or worsen, or if you've had a vaccine or plan to. (♪) start to get yourself back, with bimzelx. ask your dermatologist about bimzelx today. bent finger appointment in 30 minutes. you got this. one - remember, i don't want surgery for my dupuytren's

80 novo and eli lilly are at the top samples. me to come, but there are over 50 obesity drugs currently in development or more specifically after completely underestimating the market. the competition has now woken up with most of the students, and i'll shoot you all told to some of the home bound, which is gaining attention for its potential to provide powerful results in treating obesity. so i have some braking bound chargers the new eli lilly obese, the medication i want more and i know i shouldn't zap about actually was or the unlimited show if a new drug is not superior to its predecessor with a new product. we'll drop in price, and you don't earn anything virginia beach, there's huge competition to have the best new product or the new us from difficult . the development of artificial g, l, p one is still in its infancy. while the market is booming, obesity experts say the new drugs are not a solution to the problem for you. i'm the owner of this house. oh jan girl triumeq. the food industry still has a lot of work to do. ha

what g o p one drugs are today's golden goose and avoid that unique novo and eli lilly are at the tom sent me to come, but there are over 50 obesity drugs currently in developmental level, specifically. and after completely underestimating the market, the competition has now woken up with most of the students. i'm sure y'all told us some of the home bound, which is gaining attention for its potential to provide powerful results in treating obesity. so i have some breaking down your orders, the new eli lilly obese, the medication, i want more and i know i shouldn't zap about actually was available. i'm going to tell you if a new drug is not superior to its predecessor, the new product will drop in price and you don't earn anything. did you know? there's huge competition to have the best new product, but you know, as soon as you felt the development of artificial g, l, p one is still in its infancy. while the market is booming, obesity experts say the new drugs are not a solution to the problem or were you, i'm the owner of this house. oh yeah. and girl triumeq the food industry still h

eli lilly soaring to an all-time high, even as the fda is set to give a recommendation for an alzheimer'sly's data excludes certain patient populations that would be needed for broader approval. let's bring in nbc news medical contributor dr. kavita patel. this is going to be key in terms of what the total addressable market would be for this drug, and so, walk me through what the fda could be weighing, because it sounds like it depends on the level of that patients might have. >> let's talk about the efficacy. the trail blazer trial, which lilly ran, said there was a significant reduction in the decline in generally early stage alzheimer's patients, but when the fda in their analysis parsed that data, they saw that's generally in people that had a low to medium tow, that protein that is core lated with kind of the severity of alzheimer's, compared to people who might have more advanced alzheimer's. lilly made point, we don't think this should be a limitation, and we still think we should have broad application for this drug, and they also brought up safety concerns. and that took a long

they make basically an implant for sleep apnea, as for eli lilly it's up 1%.g a 52 week high up 5.5% after roth mkm upgraded from buy to neutral, meaningful box office improvement. it also raised its price target to $26 from $19 a share. it's at $20.55 a share. and inside out two also showing meaningful box office improvement. according to studio estimates the pixar sequal collected a record $100 million in us ticket sales in its second weekend and is predicted to blow through the $1 billion mark in about a week. that be the first film since barbie to do so. pixar is owned by disney. disney is down just a quarter of a percent but up about 12% year-to-date. thousands of food vendors are gathered just a few blocks away from fox business headquarters at the largest specialty food event in the country. up next, we're going to take you live to the floor for a peak at the gasdtronomic delights on display and look what they will cost you and marc lore the entrepreneur behind jet.com joins us in a fox business exclusive with a new food partner, michael lippold, it's a

recent trial data for eli lilly's experimental alzheimer's drug revealed no major red flags.day, but it did raise concerns about the safety of the treatment. analysts at jeffries and guggenheim all believe the drug will be approved as shares are up 1.5%. while eli lilly awaits fda approval, biopharmaceutical firm geron did get the stamp of approval for its blood disorder treatment. analysts were expecting the approval. they just weren't expecting it today, hence the stock pop, and i should say, up almost 17%. >> all right, i appreciate that, kristina partsinevelos. good weekend to you. >>> still ahead, shares of walmart, there they are, down 2% today. the company's ceo, doug mcmillon, speaking at its annual meeting just a few moments ago. we've got the highlights, and we're going to break down what is weighing on that stock specifically. the bell, right back. before you use ai to transform business, accelerate growth, predict trends, you need to begin with trust. introducing watsonx governance. helping you govern any ai, as data, models, and policies change, so you can scale

lou basenase, you're a big fan of eli lilly. i read your stuff. you think lily will go to $1 trillion market value? >> people said was too expensive and it won't go anywhere. eli lilly will be on track, if it continues at the current pace will be there by september of this year. there are multiples. they are getting into antibiotics aided by ai. the big driver is the gop loan drugs having impact on weight loss but big impact on all the other diseases downstream, liver and kidney disease and you will see over time these gop drugs continue to cure other diseases impacted by it. that is the mechanism of action. and -- and the best pipelines in the gop, it is an injectable. and down the road. stuart: you are telling nvidia shareholders, you should be able to handle a 10 or 50% drop in the stock price. it is the biggest taught gain in the market. and he looked back in history. and it takes the elevator down a little bit. you got to be prepared for that. and a lot of ups and downs. stuart: micron reporting after the bell, that an ai chip company. nvidia

stuart: fda to i approve eli lilly's alzheimer drug and they want it on the market.ed [inaudible] and similar to another one already on the market and when the fda advisers say approve, they're going to approve and it'll be available and useful for once a month and center for medicare and medicaid services made what can be available already and cover it had and they're going to make this available and cover it but the catch is may not be able to afford all the copays and tests to qualify for it and, stuart, it's got a lot of side effects and leads to brain swelling and can lead to brain bleeding and how does it work you ask? it's stops plaque formation of the beta amyloid plaques in the brain that are associated with alzheimer and not all that alzheimer is about and also about pro teen and inplay makers nation and have a long way to go before they figure this out and decreases progression by about 35% and is it worth the risk of the swelling i talked about? that's a one-on-one question and i'm glad it's going on the market. stuart: the centers for disease control war

eli lilly closing almost 2% higher, as an fda advisory panel weighs the drugmaker's alzheimer's treatmentavor of the drug's safety and efficacy. angel tica peebles has all the details. >> lilly's alzheimer's drug getting a vote of support from an fda advisory committee. the committee saying the drug is broadly effective for early disease and that the benefits outweigh the risks. the fda doesn't have to follow the recommendations of its advisers, but it usually does. lilly's drug is not a cure and only meant for people in the early stages of the disease, but it does slow progression of the disease by 29% compared to nothing at all. and the panelists heard from some of the clinical trial participants. they talked about how they're living relatively normal lives despite having alzheimer's. the committee had to weigh that against potentially deadly brain swefling and bleeding. now, we have to wait and see how the fda moves forward with these recommendations. melissa? >> who is it approved for, angelica? and do people who take it, do they have to be scanned for tau? that was sort of seen as a